Iqvia Holdings Inc (NYSE:IQV) shares reached a new 52-week high on Monday after Raymond James raised their price target on the stock from $136.00 to $145.00. Raymond James currently has a strong-buy rating on the stock. Iqvia traded as high as $127.28 and last traded at $127.09, with a volume of 736695 shares. The stock had previously closed at $125.91.

IQV has been the subject of a number of other reports. Royal Bank of Canada reiterated a “$110.25” rating and set a $128.00 target price on shares of Iqvia in a research report on Thursday, July 19th. Argus set a $136.00 target price on Iqvia and gave the company a “buy” rating in a research report on Thursday, August 23rd. Piper Jaffray Companies reiterated a “hold” rating and set a $97.00 target price on shares of Iqvia in a research report on Wednesday, July 25th. Barclays reiterated an “overweight” rating and set a $130.00 target price (up from $120.00) on shares of Iqvia in a research report on Wednesday, July 25th. Finally, Bank of America upgraded Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 target price for the company in a research report on Wednesday, July 25th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Iqvia has a consensus rating of “Buy” and an average target price of $126.79.

In related news, Director Ronald A. Rittenmeyer sold 7,680 shares of the stock in a transaction on Thursday, July 26th. The stock was sold at an average price of $122.41, for a total transaction of $940,108.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John Connaughton sold 1,441,236 shares of the stock in a transaction on Friday, June 15th. The shares were sold at an average price of $103.00, for a total value of $148,447,308.00. The disclosure for this sale can be found here. Insiders have sold a total of 11,201,623 shares of company stock worth $1,160,990,595 in the last 90 days. 6.00% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its stake in Iqvia by 5.9% in the second quarter. Bank of New York Mellon Corp now owns 1,194,110 shares of the medical research company’s stock worth $119,196,000 after purchasing an additional 66,748 shares during the period. Andra AP fonden increased its stake in Iqvia by 30.6% in the second quarter. Andra AP fonden now owns 33,300 shares of the medical research company’s stock worth $3,324,000 after purchasing an additional 7,800 shares during the period. California Public Employees Retirement System increased its stake in Iqvia by 2.0% in the second quarter. California Public Employees Retirement System now owns 361,884 shares of the medical research company’s stock worth $36,123,000 after purchasing an additional 7,202 shares during the period. Bridges Investment Management Inc. increased its stake in Iqvia by 16.1% in the second quarter. Bridges Investment Management Inc. now owns 35,013 shares of the medical research company’s stock worth $3,495,000 after purchasing an additional 4,852 shares during the period. Finally, Centaurus Financial Inc. increased its stake in Iqvia by 12.8% in the second quarter. Centaurus Financial Inc. now owns 12,357 shares of the medical research company’s stock worth $1,233,000 after purchasing an additional 1,403 shares during the period. Institutional investors own 91.98% of the company’s stock.

The company has a debt-to-equity ratio of 1.40, a current ratio of 1.13 and a quick ratio of 1.13. The company has a market capitalization of $25.75 billion, a price-to-earnings ratio of 29.37, a price-to-earnings-growth ratio of 1.82 and a beta of 0.70.

Iqvia (NYSE:IQV) last released its earnings results on Tuesday, July 24th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.15. Iqvia had a return on equity of 13.51% and a net margin of 12.68%. The business had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.50 billion. The company’s revenue was up 9.0% on a year-over-year basis. analysts expect that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

About Iqvia (NYSE:IQV)

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.